They can inhibit PD-L1 expression by inactivating STAT, AKT, and ERK signaling pathways and are also promising therapeutic manipulation targets for anti-PD-1/PD-L1 tumor immunotherapy. The gene discussed is RPL17; the disease is neoplasm.